Alnylam Pharmaceuticals Stock Market Value
| ALNY Stock | USD 324.23 3.71 1.16% |
| Symbol | Alnylam |
Alnylam Pharmaceuticals Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alnylam Pharmaceuticals. If investors know Alnylam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alnylam Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.12) | Revenue Per Share | Quarterly Revenue Growth 0.202 | Return On Assets | Return On Equity |
The market value of Alnylam Pharmaceuticals is measured differently than its book value, which is the value of Alnylam that is recorded on the company's balance sheet. Investors also form their own opinion of Alnylam Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Alnylam Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alnylam Pharmaceuticals' market value can be influenced by many factors that don't directly affect Alnylam Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alnylam Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alnylam Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alnylam Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Alnylam Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Alnylam Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Alnylam Pharmaceuticals.
| 04/23/2025 |
| 07/22/2025 |
If you would invest 0.00 in Alnylam Pharmaceuticals on April 23, 2025 and sell it all today you would earn a total of 0.00 from holding Alnylam Pharmaceuticals or generate 0.0% return on investment in Alnylam Pharmaceuticals over 90 days. Alnylam Pharmaceuticals is related to or competes with Arrowhead Pharmaceuticals, Biomarin Pharmaceutical, Incyte, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Sarepta Therapeutics, and Agios Pharm. Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing nove... More
Alnylam Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Alnylam Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Alnylam Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.04 | |||
| Information Ratio | 0.1684 | |||
| Maximum Drawdown | 12.04 | |||
| Value At Risk | (2.39) | |||
| Potential Upside | 3.98 |
Alnylam Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Alnylam Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Alnylam Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Alnylam Pharmaceuticals historical prices to predict the future Alnylam Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.2237 | |||
| Jensen Alpha | 0.4071 | |||
| Total Risk Alpha | 0.1864 | |||
| Sortino Ratio | 0.1844 | |||
| Treynor Ratio | 0.6619 |
Alnylam Pharmaceuticals Backtested Returns
Alnylam Pharmaceuticals appears to be very steady, given 3 months investment horizon. Alnylam Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.21, which signifies that the company had a 0.21 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Alnylam Pharmaceuticals, which you can use to evaluate the volatility of the firm. Please makes use of Alnylam Pharmaceuticals' Downside Deviation of 2.04, risk adjusted performance of 0.2237, and Mean Deviation of 1.61 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Alnylam Pharmaceuticals holds a performance score of 16. The firm shows a Beta (market volatility) of 0.77, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Alnylam Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Alnylam Pharmaceuticals is expected to be smaller as well. Please check Alnylam Pharmaceuticals' treynor ratio, as well as the relationship between the expected short fall and day median price , to make a quick decision on whether Alnylam Pharmaceuticals' price patterns will revert.
Auto-correlation | 0.64 |
Good predictability
Alnylam Pharmaceuticals has good predictability. Overlapping area represents the amount of predictability between Alnylam Pharmaceuticals time series from 23rd of April 2025 to 7th of June 2025 and 7th of June 2025 to 22nd of July 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Alnylam Pharmaceuticals price movement. The serial correlation of 0.64 indicates that roughly 64.0% of current Alnylam Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.64 | |
| Spearman Rank Test | 0.49 | |
| Residual Average | 0.0 | |
| Price Variance | 70.17 |
Alnylam Pharmaceuticals lagged returns against current returns
Autocorrelation, which is Alnylam Pharmaceuticals stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Alnylam Pharmaceuticals' stock expected returns. We can calculate the autocorrelation of Alnylam Pharmaceuticals returns to help us make a trade decision. For example, suppose you find that Alnylam Pharmaceuticals has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Alnylam Pharmaceuticals regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Alnylam Pharmaceuticals stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Alnylam Pharmaceuticals stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Alnylam Pharmaceuticals stock over time.
Current vs Lagged Prices |
| Timeline |
Alnylam Pharmaceuticals Lagged Returns
When evaluating Alnylam Pharmaceuticals' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Alnylam Pharmaceuticals stock have on its future price. Alnylam Pharmaceuticals autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Alnylam Pharmaceuticals autocorrelation shows the relationship between Alnylam Pharmaceuticals stock current value and its past values and can show if there is a momentum factor associated with investing in Alnylam Pharmaceuticals.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Alnylam Stock Analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.